Printer Friendly

Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards clinical studies.

HOLLYWOOD, Fla. -- Phoenix Biosciences, Inc. (PBS), focused on developing affordable, non-toxic treatments for HIV/AIDS, announced today that the U.S. Patent and trademark office has granted PBS Patent Number 6,734,192. This patent was provided to Phoenix Biosciences, Inc., for their novel immunological method, which claims to reduce HIV activity.

"The approval of this patent is an important step for our development team to move forward with clinical studies of PBS119," said Dr. Robert Keller, Chairman and CEO of Phoenix Biosciences. "Phoenix Biosciences will now aggressively pursue the execution of Phase I/II clinical trials, which will focus on patients experiencing drug resistance."

PBS119 utilizes a novel clinical approach being investigated for safety and clinical efficacy for advanced stage HIV/AIDS disease. PBS119 has been identified as having immune rebuilding potential and antiviral activity. Phoenix Biosciences is currently pursuing initial human studies that will be conducted in compliance with federal clinical trial guidelines.

Dr. Keller has been in clinical practice for the treatment of HIV/AIDS for 25 years and is certified and also sits on the Board of Governors for the Florida Chapter of the American Academy of HIV medicine. In addition, the Consumers' Research Council of America has voted Keller as one of America's top physicians in the field of immunology.

About Phoenix Biosciences, Inc.

Phoenix Biosciences, Inc., an emerging biotech company focused on developing affordable, non-toxic treatments for HIV/AIDS, Hepatitis and viral infections. The company's current lead research compound PBS119 indicates to possess broad spectrum HIV specific qualities. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company. For more information about Phoenix Biosciences, Inc., please email pbs@robkellermd.org or visit www.robkellermd.org.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 28, 2004
Words:284
Previous Article:Identify Announces AppSight J2EE 5.0.
Next Article:Fitch Ratings Assigns an 'AA-' to University of Alabama.


Related Articles
ENZO BIOCHEM GETS NEW PATENT ALLOWANCES IN U.S/CANADA.
LETTER FROM THE EDITOR.
Too smart for our own good.
Cancer and AIDS: National Cancer Institute's investment in research.
European Patent Approved for CytoDyn.
Caring for those with HIV/AIDS: nurses must continually strive to ensure the care they offer people living with HIV/AIDS is non-judgemental.
SRD Pharmaceuticals Acquires Drug Patents for New Treatment of AIDS; Will Apply to Utilize FDA's ``Fast Track'' System to Expedite Marketing Approval.
MP-1, Inc. Changes Name to Phoenix Biosciences, Inc. to Reflect Company Growth.
Advanced Biotherapy Inc. Makes Presentation at the Adult AIDS Clinical Trials Group Winter Meeting.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters